

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for identifying ~~a person with Parkinson's disease and/or~~ a person at increased risk for developing Parkinson's disease, comprising screening nucleic acids from said person for a mutation in an ADH1C gene which encodes a protein chain, said mutation causing a truncation of the expressed protein chain.

2.(original) The method according to claim 1 wherein the ADH1C gene is selected from the group consisting of a gene having a cDNA sequence of SEQ ID NO. 1 and other ADH1C genes having a thymidine at or corresponding to position 303 in SEQ ID NO. 1.

3.(previously presented) The method according to claim 1, wherein the screening comprises at least one procedure selected from the group consisting of DGGE, SSCP, HA, temperature gradient gel electrophoresis TGGE, cleavage-fragment-length polymorphism analysis CFLP, dHPLC, CCM, CDI, ECM, UNG-mediated T Scan, direct sequencing, DNA chip resequencing, Pyrosequencing™, allele-specific primer extension (GBA; TDI), oligonucleotide ligation assay (OLA; DOL), Taqman-ASO, RFLP, mass spectrometry, the

Invader™ assay, BeadArray™ technology, or any equivalent procedure which detects the mutation.

4. (previously presented) The method according to claim 1, wherein the screening comprises at least one procedure selected from the group consisting of direct sequencing, Pyrosequencing™, Taqman-ASO to specifically detect the mutation.

5. (previously presented) The method according to claim 1, wherein the screening comprises restriction enzymes specifically recognizing a nucleotide sequence of the mutation or surrounding the mutation to be detected.

6. (previously presented) The method according to claim 1, wherein the screening comprises hybridising under stringent conditions an oligonucleotide to the ADH1C gene comprising the mutation.

7-32. (canceled)